COVID-19 Vaccination for Children

Information for Jurisdictions, Clinicians, Pharmacists, Schools, Early Care and Education (ECE)/Child Care Programs, and Community Partners

The federal government is committed to ensuring that children who are eligible have access to COVID-19 vaccines. This page shares up-to-date information and resources on how to help children who are eligible get vaccinated against COVID-19.

COVID-19 Vaccination Recommendations for Children Under 12

Currently, children ages 5 through 11 years are eligible to receive the Pfizer-BioNTech COVID-19 vaccine.

Vaccine manufacturers are conducting clinical trials to assess the safety and efficacy of COVID-19 vaccination among children younger than 5 years old. Pfizer-BioNTech has begun submitting data on a three-dose primary series to FDA for an Emergency Use Authorization (EUA) application for a vaccine for children ages 6 months through 4 years. Moderna has also begun submitting data on a two-dose primary series for children aged 6 months through 5 years. The U.S. Food and Drug Administration (FDA) will review the submitted data and determine if vaccines are safe and effective and if they should be authorized for emergency use.  Following FDA authorization, CDC’s Advisory Committee on Immunization Practices (ACIP) will meet to discuss making a recommendation to the CDC director on the use of authorized vaccines based on a thorough review of the available evidence. ACIP’s decision will be sent to the CDC director for review and the CDC director makes a final determination about the use of vaccine.  If the CDC director recommends use of the vaccine, it will become available for administration.

More information on pediatric COVID-19 vaccination recommendations will be shared on this page as it becomes available.

Everyone should continue to follow all current prevention measures recommended by CDC and based on latest COVID-19 Community Level data.

Planning and Promoting COVID-19 Vaccination in Your Community
illustration of checklists

Pediatric COVID-19 Operational Planning Guidepdf icon UPDATED 5/17/2022

This operational planning guide includes details about the anticipated Pfizer-BioNTech vaccine for children ages 6 months through 4 years and the Moderna vaccine for children ages 6 months through 5 years. This guide is intended to inform planning for all current COVID-19 vaccine programs and channels for distribution of vaccine for children in these age groups, should either or both vaccines receive FDA Emergency Use Authorization (EUA) and CDC recommendation.

An overview of the differences in the Pfizer-BioNTech vaccine for adults/adolescents, the vaccine for children ages 5 through 11 years, and the vaccine for children 6 months through 4 yearspdf icon is available. A document detailing characteristics of the Moderna vaccine for children aged 6 month through 5 years is being developed.

This guide will be updated as CDC learns more about the pediatric COVID-19 vaccines.

Data and Scientific Research

Supporting Data

Published Research

FDA Updates

Clinical Training and Education for Vaccinators
Page last reviewed: May 17, 2022